<DOC>
	<DOCNO>NCT00619736</DOCNO>
	<brief_summary>This study provide initial assessment safety , tolerability pharmacokinetics ( PK ) NSA-789 administration ascend single oral dos healthy Japanese male subject . This randomized , double-blind , placebo-controlled , inpatient , sequential-group study conduct fasting condition single investigational site . Each subject participate 1 dose group receive 1 dose test article .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability Pharmacokinetics NSA-789 Healthy Japanese Male Subjects</brief_title>
	<detailed_description />
	<criteria>Men age 20 45 year inclusive screening . Healthy determine investigator basis screen evaluation . Any significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . Use investigational drug within 90 day study day 1 prescription drug within 30 day study day 1 Any clinically important deviation normal limit physical examination , vital sign , 12lead electrocardiogram ( ECGs ) , clinical laboratory test result .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Healthy</keyword>
</DOC>